Enhanced killing of ovarian carcinoma using oncolytic measles vaccine virus armed with a yeast cytosine deaminase and uracil phosphoribosyltransferase

Gynecologic Oncology

Volumn 130, Issue 2, 2013, Pages 362-368

  Hartkopf, A D ^a   Bossow, S ^b   Lampe, J ^c   Zimmermann, M ^a   Taran, F A ^a   Wallwiener, D ^a   Fehm, T ^d   Bitzer, M ^a   Lauer, U M ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c Institute for Molecular Medicine Finland FIMM   (Finland)

^d HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Ovarian cancer Virotherapy Measles vaccine virus Cytosine deaminase Chemotherapy Suicide gene therapy

Indexed keywords

5 FLUOROURIDINE MONOPHOSPHATE; CYTOSINE DEAMINASE; FLUCYTOSINE; FLUOROURACIL; FLUOROURIDINE; MEASLES VACCINE; MEASLES VACCINE VIRUS; UNCLASSIFIED DRUG; URACIL PHOSPHORIBOSYLTRANSFERASE; YEAST CYTOSINE DEAMINASE;

ARTICLE; CELL KILLING; CELL LINE; CELLS; CONTROLLED STUDY; DRUG SAFETY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALIGNANT ASCITES; OVARY CANCER; OVARY CARCINOMA; PATIENT; PRIMARY TUMOR; PRIORITY JOURNAL; SUICIDE GENE THERAPY;

CHEMOTHERAPY; CYTOSINE DEAMINASE; MEASLES VACCINE VIRUS; OVARIAN CANCER; SUICIDE GENE THERAPY; VIROTHERAPY;

CELL LINE, TUMOR; CYTOSINE DEAMINASE; FEMALE; FLUCYTOSINE; GENETIC THERAPY; HUMANS; MEASLES VACCINE; MEASLES VIRUS; ONCOLYTIC VIROTHERAPY; OVARIAN NEOPLASMS; PENTOSYLTRANSFERASES; SACCHAROMYCES CEREVISIAE;

EID: 84880289348     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2013.05.004     Document Type: Article

References (25)

1. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2012 CA Cancer J Clin 62 2012 10 29
2. S. Vaughan, J.I. Coward, R.C. Bast Jr., A. Berchuck, J.S. Berek, and J.D. Brenton Rethinking ovarian cancer: recommendations for improving outcomes Nat Rev Cancer 11 2011 719 725
3. A.D. Hartkopf, T. Fehm, D. Wallwiener, and U. Lauer Oncolytic virotherapy of gynecologic malignancies Gynecol Oncol 120 2011 302 310
4. M. Bitzer, and U.M. Lauer Oncolytic viruses for genetic therapy of gastrointestinal tumors Z Gastroenterol 41 2003 667 674
5. E. Galanis, L.C. Hartmann, W.A. Cliby, H.J. Long, P.P. Peethambaram, and B.A. Barrette Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer Cancer Res 70 2010 875 882
6. K.W. Peng, C.J. TenEyck, E. Galanis, K.R. Kalli, L.C. Hartmann, and S.J. Russell Intraperitoneal therapy of ovarian cancer using an engineered measles virus Cancer Res 62 2002 4656 4662
7. P.A. Vasey, L.N. Shulman, S. Campos, J. Davis, M. Gore, and S. Johnston Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer J Clin Oncol 20 2002 1562 1569
8. H.L. Liu, and J. Chen Oncolytic virus as an agent for the treatment of malignant ascites Cancer Biother Radiopharm 24 2009 99 102
9. D.T. Curiel, M. Preuss, M. Wang, K.J. Kimball, M.N. Barnes, and W. Wan A phase I study of the infectivity enhanced CRAd Ad5-delta24RGD for recurrent gynecologic cancer J Clin Oncol 28 2010 15s [abstr 5107]
10. J.A. Bridgewater, C.J. Springer, R.J. Knox, N.P. Minton, N.P. Michael, and M.K. Collins Expression of the bacterial nitroreductase enzyme in mammalian cells renders them selectively sensitive to killing by the prodrug CB1954 Eur J Cancer 31A 1995 2362 2370
11. P. Erbs, E. Regulier, J. Kintz, P. Leroy, Y. Poitevin, and F. Exinger In vivo cancer gene therapy by adenovirus-mediated transfer of a bifunctional yeast cytosine deaminase/uracil phosphoribosyltransferase fusion gene Cancer Res 60 2000 3813 3822
12. M. Zimmermann, S. Armeanu, I. Smirnow, S. Kupka, S. Wagner, and M. Wehrmann Human precision-cut liver tumor slices as a tumor patient-individual predictive test system for oncolytic measles vaccine viruses Int J Oncol 34 2009 1247 1256
13. M. Zimmermann, T. Weiland, M. Bitzer, and U.M. Lauer Preclinical testing of virotherapeutics for primary and secondary tumors of the liver Methods Mol Biol 806 2012 121 136
14. P.A. Kruk, S.L. Maines-Bandiera, and N. Auersperg A simplified method to culture human ovarian surface epithelium Lab Invest 63 1990 132 136
15. S. Berchtold, J. Lampe, T. Weiland, I. Smirnow, S. Schleicher, and R. Handgretinger Innate immune defense defines susceptibility of sarcoma cells to measles vaccine virus-based oncolysis J Virol 87 2013 3484 3501
16. W.A. Wybranietz, F. Prinz, M. Spiegel, A. Schenk, M. Bitzer, and M. Gregor Quantification of VP22-GFP spread by direct fluorescence in 15 commonly used cell lines J Gene Med 1 1999 265 274
17. P. Skehan, R. Storeng, D. Scudiero, A. Monks, J. McMahon, and D. Vistica New colorimetric cytotoxicity assay for anticancer-drug screening J Natl Cancer Inst 82 1990 1107 1112
18. I.D. Iankov, B. Blechacz, C. Liu, J.D. Schmeckpeper, J.E. Tarara, and M.J. Federspiel Infected cell carriers: a new strategy for systemic delivery of oncolytic measles viruses in cancer virotherapy Mol Ther 15 2007 114 122
19. M.R. Hilleman Current overview of the pathogenesis and prophylaxis of measles with focus on practical implications Vaccine 20 2001 651 665
20. C. Pisano, A. Morabito, R. Sorio, E. Breda, R. Lauria, and V. Gebbia A phase II study of capecitabine in the treatment of ovarian cancer resistant or refractory to platinum therapy: a multicentre Italian trial in ovarian cancer (MITO-6) trial Cancer Chemother Pharmacol 64 2009 1021 1027
21. K.Y. Look, J.A. Blessing, H.B. Muss, E.E. Partridge, and J.H. Malfetano 5-fluorouracil and low-dose leucovorin in the treatment of recurrent squamous cell carcinoma of the cervix. A phase II trial of the Gynecologic Oncology Group Am J Clin Oncol 15 1992 497 499
22. S. Chalikonda, M.H. Kivlen, M.E. O'Malley, X.D. Eric Dong, J.A. McCart, and M.C. Gorry Oncolytic virotherapy for ovarian carcinomatosis using a replication-selective vaccinia virus armed with a yeast cytosine deaminase gene Cancer Gene Ther 15 2008 115 125
23. P. Newell, A. Villanueva, S.L. Friedman, K. Koike, and J.M. Llovet Experimental models of hepatocellular carcinoma J Hepatol 48 2008 858 879
24. K.K. Frese, and D.A. Tuveson Maximizing mouse cancer models Nat Rev Cancer 7 2007 645 658
25. A.D. Hartkopf, T. Fehm, D. Wallwiener, and U.M. Lauer Oncolytic virotherapy of breast cancer Gynecol Oncol 123 2011 164 171